CYP2C9 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 17 of 17 results for "CYP2C9"
i
  1. Crystal structure of CYP2C9 in complex with an inhibitor PDB

    ID: PDB:4NZ2

    Description: Cytochrome P450 2C9 (E.C.1.14.13.-, 1.14.13.80, 1.14.13.48, 1.14.13.49)

  2. STRUCTURE OF HUMAN CYTOCHROME P450 CYP2C9 PDB

    ID: PDB:1OG2

    Description: CYTOCHROME P450 2C9 (E.C.1.14.13.80, 1.14.13.48, 1.14.13.49)

  3. STRUCTURE OF HUMAN CYTOCHROME P450 CYP2C9 PDB

    ID: PDB:1OG5

    Description: CYTOCHROME P450 2C9 (E.C.1.14.13.80, 1.14.13.48, 1.14.13.49)

  4. ibosyltransferase (NAMPT) Inhibitors with Reduced CYP2C9 Inhibition Properties... PDB

    ID: PDB:4JNM

    Description: Nicotinamide phosphoribosyltransferase (E.C.2.4.2.12)

  5. Design and Optimization of Biaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7: Discovery of Clinical Candidate PF-05089771 PDB

    ID: PDB:5K7K

    Description: Cytochrome P450 2C9 (E.C.1.14.13.80)

  6. Crystal Structure of P4502C9 with Flurbiprofen bound PDB

    ID: PDB:1R9O

    Description: Cytochrome P450 2C9 (E.C.1.14.14.1)

  7. Cytochrome 2C9 P450 inhibitor complex PDB

    ID: PDB:5A5I

    Description: CYTOCHROME P450 2C9

  8. Warfarin Pharmacogenetics: Pharmacogenetic Optimization of Anticoagulant Response (POAT) and Genetic and Environmental Determinants of Warfarin Respon... dbGaP

    ID: phs000708.v1.p1

    Description: e cohort study aimed at defining the influence of CYP2C9, VKORC1 and other genes. All patients were followed at monthly intervals from initiation of therapy. At each visit factors influencing warfarin response such as warfarin dose, INR, concurrent medications, etc. were documented. Information on concurrent medications was updated at every clinic visit by self-report and verified by medical record review. Concomitant use of drugs such as drugs that alter warfarin pharmacokinetics, including CYP2C9 inhibitors (e.g., amiodarone), and pharmacodynamics such as antiplatelet agents (e.g. aspirin). Although the a priori hypothesis focused on the candidate-gene approach, with the recognition that the candidate-gene approach is bound by the assumption that our knowledge of genetic influences on warfarin response is complete. Among African Americans known variation in candidate genes (CYP2C9 and VKORC1) explain substantially less variability in warfarin dose ...

    Study Types: Cohort

  9. Evolved variant of cytochrome P450 (BM3, CYP102A1) PDB

    ID: PDB:3QI8

    Description: Evolved Cytochrome P450 variant (22A3) (E.C.1.14.14.1)

  10. Crystal Structure of Nicotinamide Phosphoribosyltransferase (Nampt) in Complex with Inhibitors 37 PDB

    ID: PDB:5KIT

    Description: Nicotinamide phosphoribosyltransferase (E.C.2.4.2.12)

    primaryPublication.title: Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
  11. Cytochrome 2C9 P450 inhibitor complex PDB

    ID: PDB:5A5J

    Description: CYTOCHROME P450 2C9 (E.C.1.14.99.38)

  12. Pharmacogenetic Optimization of Anticoagulant Response (POAT) and Genetic and Environmental Determinants of Warfarin Response (GEDWR) BioProject

    ID: PRJNA236404

    Keywords: Phenotype or Genotype

    Access Type: download

    dataset.description: e cohort study aimed at defining the influence of CYP2C9, VKORC1 and other genes. All patients were followed at monthly intervals from initiation... (for more see dbGaP study page.)...
  13. Pharmacogenetic Optimization of Anticoagulant Response (POAT) and Genetic and Environmental Determinants of Warfarin Response (GEDWR) BioProject

    ID: PRJNA236403

    Access Type: download

    dataset.description: e cohort study aimed at defining the influence of CYP2C9, VKORC1 and other genes. All patients were followed at monthly intervals from initiation... (for more see dbGaP study page.)...
  14. Gene Expression Analysis in Peripheral Blood of Patients with Rheumatoid Arthritis OmicsDI

    ID: E-GEOD-12653

    Date Released: 05-01-2014

    Description: ncreased to some extent at day 42 was observed in 2 of 18 subjects. In other subjects, quite small change or small increase after day 7 was observed. (2) In the case of IL-6R as well as in IL-6, the specific time profile that the expression level dropped at day 21 and increased to some extent at day 42 was observed in 1 of 18 subjects. In other subjects, slow and small increase was observed in 6 of 18. (3) The ratio of mRNA expression level of membrane and soluble ...

  15. Gene Expression Analysis in Peripheral Blood of Patients with Rheumatoid Arthritis ArrayExpress

    ID: E-GEOD-12653

    Description: ncreased to some extent at day 42 was observed in 2 of 18 subjects. In other subjects, quite small change or small increase after day 7 was observed. (2) In the case of IL-6R as well as in IL-6, the specific time profile that the expression level dropped at day 21 and increased to some extent at day 42 was observed in 1 of 18 subjects. In other subjects, slow and small increase was observed in 6 of 18. (3) The ratio of mRNA expression level of membrane and soluble ...

  16. Additional file 1: Sheet 1. of A multi-factorial analysis of response to warfarin in a UK prospective cohort Figshare

    ID: doi:10.6084/M9.FIGSHARE.C.3642080_D2

    Release Date: 12-16-2016

    Description: tly the sum of these coefficients was used. Sheet 2. List of all concomitant drugs taken by patients. Sheet 3. Top signals from linear regressions on SMWD. P values marked with an asterisk were obtained from the regression only adjusting for non-genetic factors, while other P values where obtained from a multiple regression after conditioning on rs9923231, rs1799853 and rs1057910. Sheet 4. Top signals from logistic regressions on INR >4 during first week of treatment. P values marked with an asterisk were obtained from the reg...

  17. Gene Expression Analysis in Peripheral Blood of Patients with Rheumatoid Arthritis BioProject

    ID: PRJNA113057

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: ncreased to some extent at day 42 was observed in 2 of 18 subjects. In other subjects, quite small change or small increase after day 7 was observed. (2) In the case of IL-6R as well as in IL-6, the specific time profile that the expression level dropped at day 21 and increased to some extent at day 42 was observed in 1 of 18 subjects. In other subjects, slow and small increase was observed in 6 of 18. (3) The ratio of mRNA expression level of membrane and soluble ...

Displaying 17 of 17 results for "CYP2C9"